At a glance
- Originator Eisai Co Ltd
- Mechanism of Action Serotonin 1A receptor antagonists; Serotonin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Muscle spasticity
Most Recent Events
- 17 Apr 2000 Phase-I clinical trials for Spasticity in Japan (Unknown route)